About the Summit
Rational drug design and development are crucial steps in R&D initiatives where the intrinsic properties of a drug candidate, such as ADME/T, stability, and solubility, are established and enhanced. These important properties have significant implications to a molecule’s chance of success in the later stage of preclinical development and clinical evaluation, yet current empirical-centric research methods fail to help reliably evaluate a drug candidate’s safety and efficacy, leading to wasted resources and efforts. At the same time, exciting advancements in data analytics, machine learning, cloud computing, and other computational technologies are giving rise to a new generation of algorithm-driven tools that hold the promise of significantly improving the efficiency and success rate of drug design and development. From crystal structure prediction to AI-powered molecular simulation, new technologies are now accessible to address the unmet scientific needs in late drug discovery and early drug development, with encouraging results and exciting case studies that point to an increasingly digital future of drug R&D.
The Rational Solid Form Design Summit hopes to facilitate conversations between trailblazing researchers and industry players in the field of rational drug design and development and bridge the gap between newly available technologies and pharmaceutical research. The summit also offers insights on data strategy, IT security, and patent strategies relevant to implementing new technologies into existing R&D workflows to help pharmaceutical key decision-makers prepare for the future R&D and mitigate new challenges.
RSFD 2019 Organizing Committee
Professor of Chemistry
University of Luxembourg
VP, Scientific Affairs
Director of Communications
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi’s ID4 platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide.
Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since built an elite team with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi’s cutting-edge technologies, innovative solutions, and diverse applications across the pharmaceutical value chain have helped it gain industry approval and establish strategic partnerships with top international pharmaceutical companies.
CCDC are world-leading experts in structural chemistry data, software, and knowledge for materials and life science research and application. CCDC specializes in the collation, preservation, and application of scientific structural data for use in pharmaceutical discovery, materials development, and research and education.
CCDC compiles and distributes the Cambridge Structural Database (CSD), a certified trusted database of fully curated and enhanced organic and metal-organic structures, used by researchers across the globe. CCDC's cutting-edge software empowers scientists to extract invaluable insights from the vast dataset, informing and accelerating their research & development.
Amazon Web Services (AWS) is the world’s most comprehensive and broadly adopted cloud platform, offering over 165 fully featured services from data centers globally. Millions of customers —including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs.